{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:27:07Z","timestamp":1787218027873,"version":"build-2736575974"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterized by fluctuating skeletal muscle weakness. Although the pathogenic roles of autoantibodies targeting the acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and certain neuromuscular junction proteins have been well established, increasing evidence indicates that MG onset, progression, and therapeutic response can be shaped by the complex interactions within diverse immune microenvironments. Particularly, population heterogeneity, including differences in antibody subtype, age, sex, genetic susceptibility, ethnicity, thymic pathology, and potential confounders related to differences in healthcare conditions, strongly contributes to variability in its clinical manifestations and targeted therapies. This review discusses current evidence on the roles of the immune microenvironment and individual heterogeneity in shaping the pathogenesis and treatment landscape of MG. Along with the contributions of immunophenotyping, multi-omics techniques, single-cell and spatial transcriptomics, and biomarker discovery in improving our understanding of MG mechanisms, we also evaluated the implications of immune diversity in various populations for established therapies, as well as emerging immune-modulating approaches. This review highlights current knowledge gaps and future research priorities, emphasizing the transition from phenotype-based disease classification toward immune endotype-driven precision medicine within population heterogeneity.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1932949","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:07:06Z","timestamp":1787216826000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics"],"prefix":"10.3389","volume":"17","author":[{"given":"Xia","family":"Xue","sequence":"first","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjing","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Henan Key Laboratory for Helicobacter pylori and Digestive Tract Microecology, The Fifth Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2026.e00837","article-title":"Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies","volume":"23","author":"Fuchs","year":"2026","journal-title":"Neurotherapeutics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3892\/ijmm.2026.5769","article-title":"The role and mechanism of IL-35 in myasthenia gravis (Review)","volume":"57","author":"Mao","year":"2026","journal-title":"Int J Mol Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1739730","article-title":"Association between vaccination and myasthenia gravis: a systematic review and meta-analysis","volume":"17","author":"Guan","year":"2026","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/cells13181550","article-title":"Non-coding RNAs in myasthenia gravis: From immune regulation to personalized medicine","volume":"13","author":"Iacomino","year":"2024","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70309","article-title":"Beyond the surface: Investigating the potential mechanisms of non-motor symptoms in myasthenia gravis","volume":"32","author":"Wang","year":"2025","journal-title":"Eur J Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502480","article-title":"A clinical perspective on muscle specific kinase antibody positive myasthenia gravis","volume":"15","author":"Keritam","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2408324121","article-title":"Agonist antibody to MuSK protects mice from MuSK myasthenia gravis","volume":"121","author":"Oury","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive myasthenia gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000214428","article-title":"Outcomes in relation to the age at onset in patients with myasthenia gravis","volume":"105","author":"Huang","year":"2025","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200220","article-title":"Functional signature of LRP4 antibodies in myasthenia gravis","volume":"11","author":"Chuquisana","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1508422","article-title":"Advances in the genetics of myasthenia gravis: insights from cutting-edge neuroscience research","volume":"11","author":"Yixian","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000001088","article-title":"Novel pathophysiological insights in autoimmune myasthenia gravis","volume":"35","author":"Masi","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1404191","article-title":"Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxag010","article-title":"Single-cell RNA-sequencing of myasthenia gravis reveals transcriptional heterogeneity and dysfunction of immune cell populations","volume":"38","author":"Wu","year":"2026","journal-title":"Int Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1648020","article-title":"Inflammatory imbalance and activation deficits in T cells of myasthenia gravis patients revealed by proteomic profiling","volume":"16","author":"Bhandage","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21037\/med-25-12","article-title":"Thymic hyperplasia in myasthenia gravis: a narrative review","volume":"9","author":"Sikorski","year":"2025","journal-title":"Mediastinum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70436","article-title":"Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis","volume":"15","author":"Li","year":"2025","journal-title":"Clin Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1370411","article-title":"Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities","volume":"15","author":"Ma","year":"2024","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103395","article-title":"Peripheral immune profiling highlights a dynamic role of low-density granulocytes in myasthenia gravis","volume":"152","author":"Zhang","year":"2025","journal-title":"J Autoimmun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000945","article-title":"Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000529626","article-title":"Aberrant dendritic cell subsets in patients with myasthenia gravis and related clinical features","volume":"30","author":"Song","year":"2023","journal-title":"Neuroimmunomodulation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107880","article-title":"Natural killer cells promote the differentiation of follicular helper T cells instead of inducing apoptosis in myasthenia gravis","volume":"98","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103875","article-title":"Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells","volume":"24","author":"Man\u00e9-Damas","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102800","article-title":"The role of innate immunity in myasthenia gravis","volume":"20","author":"Zhao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac084","article-title":"The potential for treg-enhancing therapies in nervous system pathologies","volume":"211","author":"Olson","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01784.x","article-title":"Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis","volume":"127","author":"Yarilin","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2025.05.002","article-title":"Processivity and BDNF-dependent modulation of signalling endosome axonal transport are impaired in mice with advanced age","volume":"153","author":"Villarroel-Campos","year":"2025","journal-title":"Neurobiol Aging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.3390\/ijms24043073","article-title":"Relationship between hypoxic and immune pathways activation in the progression of neuroinflammation: Role of HIF-1\u03b1 and Th17 cells","volume":"24","author":"Arias","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-024-01610-w","article-title":"TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models","volume":"27","author":"Wilson","year":"2024","journal-title":"Nat Neurosci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103669","article-title":"Towards personalized management of myasthenia gravis phenotypes: From the role of multi-omics to the emerging biomarkers and therapeutic targets","volume":"23","author":"Balistreri","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000431036","article-title":"Geographical distribution of myasthenia gravis in Northern Europe--Results from a population-based study from two countries","volume":"44","author":"Boldingh","year":"2015","journal-title":"Neuroepidemiology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1159\/000500268","article-title":"A prospective study of the incidence of myasthenia gravis in the East Midlands of England","volume":"53","author":"Maddison","year":"2019","journal-title":"Neuroepidemiology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/nyas.13471","article-title":"A unique subphenotype of myasthenia gravis","volume":"1412","author":"Heckmann","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578524","article-title":"Seasonal variation in myasthenia gravis incidence","volume":"399","author":"Falso","year":"2025","journal-title":"J Neuroimmunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000214150","article-title":"Subunit-specific immunodominance in clinically distinct populations with AChR+ myasthenia gravis: A multiparametric cross-sectional analysis","volume":"105","author":"Oved","year":"2025","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.199679","article-title":"Cellular immune endophenotypes separating early and late-onset myasthenia gravis","volume":"11","author":"Theorell","year":"2026","journal-title":"JCI Insight"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.10.669569","article-title":"B cell tolerance and BCR signaling dysregulation in NF155-mediated autoimmune nodopathies","volume":"12","author":"Roy","year":"2025","journal-title":"Biorxiv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"9142","DOI":"10.3390\/ijms22179142","article-title":"Laboratory investigation of hybrid IgG4 k\/\u03bb in MuSK positive myasthenia gravis","volume":"22","author":"Basile","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01380-0","article-title":"Pharmacokinetics and pharmacodynamics of nipocalimab, a neonatal Fc receptor blocker, in healthy Japanese volunteers","volume":"44","author":"Matsushima","year":"2024","journal-title":"Clin Drug Investig"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100987","article-title":"Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis","volume":"7","author":"Dodd","year":"2026","journal-title":"Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/brainsci15090978","article-title":"Immunological targets in generalized myasthenia gravis treatment: Where are we going now","volume":"15","author":"Rossini","year":"2025","journal-title":"Brain Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110560","article-title":"Measuring efficacy for myasthenia gravis treatments: A review of biomarkers used in clinical trials","volume":"280","author":"Wesley","year":"2025","journal-title":"Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1608160","article-title":"Subtype-specific atypical B cell profiles in myasthenia gravis reveal distinct immunopathological pathways","volume":"16","author":"Sikorski","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28227","article-title":"Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis","volume":"70","author":"Huang","year":"2024","journal-title":"Muscle Nerve"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s374694","article-title":"Ravulizumab in myasthenia gravis: A review of the current evidence","volume":"19","author":"Vu","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy","volume":"31","author":"Sacc\u00e0","year":"2024","journal-title":"Eur J Neurol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110499","article-title":"Inflammation and autoimmune myasthenia gravis","volume":"14","author":"Huda","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26169","article-title":"Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease","volume":"90","author":"Handunnetthi","year":"2021","journal-title":"Ann Neurol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1759-7714.2012.00121.x","article-title":"PTPN22 and CTLA-4 gene polymorphisms in resected thymomas and thymus for myasthenia gravis","volume":"3","author":"Zheng","year":"2012","journal-title":"Thorac Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.04.006","article-title":"Myasthenia gravis. Update on diagnosis and therapy","volume":"161","author":"Garc\u00eda Est\u00e9vez","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000003504","article-title":"A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland","volume":"88","author":"Lefter","year":"2017","journal-title":"Neurology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1555075","article-title":"The burden of disease in seronegative myasthenia gravis: a patient-centered perspective","volume":"16","author":"Lehnerer","year":"2025","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern Emerg Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e3181d7d884","article-title":"Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis","volume":"74","author":"Cavalcante","year":"2010","journal-title":"Neurology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13054-024-05006-x","article-title":"Gut-derived immune cells and the gut-lung axis in ARDS","volume":"28","author":"Ziaka","year":"2024","journal-title":"Crit Care"},{"key":"B61","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/jof9050569","article-title":"Fungal gut microbiome in myasthenia gravis: a sub-analysis of the MYBIOM study","volume":"9","author":"Verhasselt","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/mus.28282","article-title":"Longitudinal relationships between free-living activities, fatigue, and symptom severity in myasthenia gravis using cohort and individualized models","volume":"71","author":"Dimmick","year":"2025","journal-title":"Muscle Nerve"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114677","article-title":"Spatial transcriptomics elucidates medulla niche supporting germinal center response in myasthenia gravis-associated thymoma","volume":"43","author":"Yasumizu","year":"2024","journal-title":"Cell Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"23978","DOI":"10.1038\/s41598-025-10055-5","article-title":"The role of regulatory B cell\/T follicular helper cell balance in thymoma and thymoma-associated myasthenia gravis","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.09.003","article-title":"An intracellular adrenomedullin system reduces IL-6 release via a NF-kB-mediated, cAMP-independent transcriptional mechanism in rat thymic epithelial cells","volume":"88","author":"Castellani","year":"2016","journal-title":"Cytokine"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06843.x","article-title":"Experimental myasthenia gravis in Aire-deficient mice: a link between Aire and regulatory T cells","volume":"1275","author":"Aricha","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14195","article-title":"Myasthenia gravis and specific immunotherapy: monoclonal antibodies","volume":"1452","author":"Cai","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020503","article-title":"Perisynaptic Schwann cells at the neuromuscular synapse: Adaptable, multitasking glial cells","volume":"7","author":"Ko","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.24231","article-title":"Clinical relevance of terminal Schwann cells: An overlooked component of the neuromuscular junction","volume":"96","author":"Santosa","year":"2018","journal-title":"J Neurosci Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2021.103590","article-title":"Macrophage roles in peripheral nervous system injury and pathology: Allies in neuromuscular junction recovery","volume":"111","author":"Rios","year":"2021","journal-title":"Mol Cell Neurosci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: Pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1277596","article-title":"Role of complement in myasthenia gravis","volume":"14","author":"San","year":"2023","journal-title":"Front Neurol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-026-00900-8","article-title":"Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis","volume":"14","author":"Ao","year":"2026","journal-title":"biomark Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40478-026-02284-0","article-title":"Complement deposition, IgG subtyping and endplate destruction in LRP4-ab-positive myasthenia gravis","volume":"14","author":"Hoffmann","year":"2026","journal-title":"Acta Neuropathol Commun"},{"key":"B76","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s00415-026-13778-1","article-title":"Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis","volume":"273","author":"Filippakopoulou","year":"2026","journal-title":"J Neurol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.3390\/jcm14207235","article-title":"Innate immunity in the pathogenesis of selected autoimmune neurological diseases","volume":"14","author":"Rudnicka-Czerwiec","year":"2025","journal-title":"J Clin Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"578941","DOI":"10.1016\/j.jneuroim.2026.578941","article-title":"Real-world evidence on utilization and clinical outcomes of efgartigimod in patients with generalized myasthenia gravis","volume":"417","author":"Miguet","year":"2026","journal-title":"J Neuroimmunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/25785826.2020.1724756","article-title":"Antigen specific B cells in myasthenia gravis patients","volume":"43","author":"Takata","year":"2020","journal-title":"Immunol Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","author":"Vesperinas-Castro","year":"2023","journal-title":"Front Neurol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","article-title":"Myasthenia gravis in 2025: five new things and four hopes for the future","volume":"272","author":"Binks","year":"2025","journal-title":"J Neurol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aeb6424","article-title":"BCMA\/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares","volume":"12","author":"Huang","year":"2026","journal-title":"Sci Adv"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200384","article-title":"Single-cell transcriptomics identifies a prominent role for the MIF-CD74 axis in myasthenia gravis thymus","volume":"12","author":"Terroba-Navajas","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel treatments in myasthenia gravis","volume":"11","author":"Menon","year":"2020","journal-title":"Front Neurol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200455","article-title":"Unknown immunoregulatory effects of FcRn inhibition by efgartigimod in myasthenia gravis: a new mechanism of action beyond IgG reduction","volume":"12","author":"Tarasco","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115153","article-title":"FcRn inhibition with efgartigimod ameliorates muscle weakness and modulates dendritic cell subsets in an experimental autoimmune myasthenia gravis mouse model","volume":"162","author":"Shi","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"J Clin Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1746161","article-title":"Neuroinflammation: a critical bridge linking peripheral pathology and age-related degeneration in myasthenia gravis","volume":"13","author":"Liu","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2007.05.023","article-title":"Nonthymoma early-onset- and late-onset-generalized myasthenia gravis--a retrospective hospital-based study","volume":"109","author":"Chan","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1423895","article-title":"Myasthenia gravis complicated with pulmonary infection by Nocardia cyriacigeorgica: a case report and literature review","volume":"11","author":"Zuo","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597259","article-title":"Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review","volume":"16","author":"S\u00e1nchez-Camacho","year":"2025","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s243519","article-title":"Prognostic analysis of thymoma-associated myasthenia gravis (MG) in Chinese patients and its implication of MG management: experiences from a tertiary hospital","volume":"16","author":"Chen","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1515\/jpm-2020-0163","article-title":"Maternal and neonatal outcomes among pregnant women with myasthenia gravis","volume":"48","author":"Nicholls-Dempsey","year":"2020","journal-title":"J Perinat Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/genes13040696","article-title":"Preferential X chromosome inactivation as a mechanism to explain female preponderance in myasthenia gravis","volume":"13","author":"Nicol\u00ec","year":"2022","journal-title":"Genes (Basel)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211010105","article-title":"Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection","volume":"12","author":"Salciccia","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B98","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13293-026-00857-1","article-title":"Sex differences in immune modulation: implications for infection, inflammation, and nutritional supplementation","volume":"17","author":"Ara\u00fajo","year":"2026","journal-title":"Biol Sex Differ"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/mus.70022","article-title":"Association of race and social determinants of health with exacerbations in generalized myasthenia gravis","volume":"72","author":"Jackson","year":"2025","journal-title":"Muscle Nerve"},{"key":"B100","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/antib8040056","article-title":"Understanding inter-individual variability in monoclonal antibody disposition","volume":"8","author":"Thomas","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578803","article-title":"Diversity of childhood-onset myasthenia gravis: pathophysiology and treatment","volume":"411","author":"Hayashi","year":"2026","journal-title":"J Neuroimmunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.834212","article-title":"The epidemiology and phenotypes of ocular manifestations in childhood and juvenile myasthenia gravis: a review","volume":"13","author":"Heckmann","year":"2022","journal-title":"Front Neurol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awag215","article-title":"Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide","volume":"23","author":"Vincent","year":"2026","journal-title":"Brain"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2012.8.3.161","article-title":"Incidence of thymoma in myasthenia gravis: a systematic review","volume":"8","author":"Mao","year":"2012","journal-title":"J Clin Neurol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69791","article-title":"Correlation between the prevalence of myasthenia gravis and the frequency of class II human leucocyte antigen alleles in various geographical locations around the world","volume":"16","author":"Kurian","year":"2024","journal-title":"Cureus"},{"key":"B107","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm-19-363","article-title":"Serological diagnosis of myasthenia gravis and its clinical significance","volume":"11","author":"Li","year":"2023","journal-title":"Ann Transl Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50692","article-title":"Exacerbation of thymoma-associated myasthenia gravis following efgartigimod treatment related to anti-acetylcholine receptor antibody overshoot: a report of two cases","volume":"15","author":"Kawama","year":"2023","journal-title":"Cureus"},{"key":"B109","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41421-021-00314-w","article-title":"Single-cell RNA-Seq reveals transcriptional heterogeneity and immune subtypes associated with disease activity in human myasthenia gravis","volume":"7","author":"Jin","year":"2021","journal-title":"Cell Discov"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119873","article-title":"Serum metabolomic profile of myasthenia gravis and potential values as biomarkers in disease monitoring","volume":"562","author":"Sha","year":"2024","journal-title":"Clin Chim Acta"},{"key":"B111","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11306-019-1571-9","article-title":"Beyond the antibodies: serum metabolomic profiling of myasthenia gravis","volume":"15","author":"Blackmore","year":"2019","journal-title":"Metabolomics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932949\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:07:08Z","timestamp":1787216828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932949\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":111,"alternative-id":["10.3389\/fimmu.2026.1932949"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1932949","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1932949"}}